Shopping Cart
Remove All
Your shopping cart is currently empty
R1487
Copy Product Info
😃Good
Catalog No. T7667Cas No. 449811-92-1
R1487 is an orally bioavailable and highly selective p38α mitogen-activated protein kinase inhibitor.
R1487
Copy Product Info😃Good
Purity: 99.77%
Catalog No. T7667Cas No. 449811-92-1
R1487 is an orally bioavailable and highly selective p38α mitogen-activated protein kinase inhibitor.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $133 | In Stock | In Stock | |
| 5 mg | $298 | In Stock | In Stock | |
| 10 mg | $453 | In Stock | In Stock | |
| 25 mg | $747 | In Stock | In Stock | |
| 50 mg | $1,050 | In Stock | In Stock | |
| 100 mg | $1,420 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.77%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
R1487 AI Summary
R1487 exhibits a broad spectrum of bioactivities. It shows potent inhibitory effects on a variety of kinases and proteins, including p38alpha, P38beta, ADCK3, CSNK1epsilon, DDR1, GAK, JNK1, JNK2, JNK3, NLK, RSK2, and STK36, with Kd values ranging from 0.2 nM to 1000.0 nM. It also inhibits TNF-alpha-induced IL-6 and IL-1beta production and LPS-induced TNF-alpha and IL-6 production. The compound demonstrates analgesic activity in a rat model and has favorable pharmacokinetic properties such as a Tmax of 4.67 hr, Cmax of 4016.79 nM, a half-life of 22.5 hr, an AUC of 29400.0 ng.hr.mL-1, an oral bioavailability of 51.6%, and clearance of 3.05 mL.min-1.kg-1. While it binds extensively to plasma proteins in cynomolgus monkeys, it has low aqueous solubility and permeability in human Caco-2 cells.
Additionally, R1487 reveals lower affinity for kinases such as CLK2, PLK3, CSNK1G2, PRKCZ, STK3 with Ki values exceeding 7943.28 nM, and for targets like CDC42BPA, AKT3, CDK5 with Ki values above 10000.0 nM. It shows moderate inhibitory activity against Plasmodium falciparum proliferation with potencies ranging from 9432.9 nM to 14950.2 nM. The compound has a LogD7.4 value of 2.76 and a solubility of 20400.0 nM at pH 7.4.
Importantly, R1487 demonstrates potent antiviral activity, inhibiting the SARS-CoV-2 3CL-Pro protease by 92.81% at 20µM, and reducing SARS-CoV-2 induced cytotoxicity in VERO-6 cells at 10 µM with an inhibition rate of -0.09% after 48 hours. These attributes highlight its potential as an antiviral agent, particularly against SARS-CoV-2..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | R1487 is an orally bioavailable and highly selective p38α mitogen-activated protein kinase inhibitor. |
| Molecular Weight | 388.37 |
| Formula | C19H18F2N4O3 |
| Cas No. | 449811-92-1 |
| Smiles | Cn1c2nc(NC3CCOCC3)ncc2cc(Oc2ccc(F)cc2F)c1=O |
| Relative Density. | 1.425 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: Slightly soluble  |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy R1487 | purchase R1487 | R1487 cost | order R1487 | R1487 chemical structure | R1487 formula | R1487 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.